NEW YORK, February 26, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited MESOMSB)), a global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2022.

The webcast begins Monday, February 27 at 4:30 p.m. EST; 8:30 a.m. AEDT, Tuesday, February 28; 2023. Accessible via: https://webcast.openbriefing.com/msb-qtr-2023/

The archived webcast will be available on the Investors page of the Company’s website: www.mesoblast.com

About mesoblast
Mesoblast is a global leader in the development of allogeneic (ready-to-use) cellular drugs to treat serious and life-threatening inflammatory diseases. The Company has leveraged its proprietary mesenchymal lineage cell therapy platform to establish a broad portfolio of late-stage product candidates that address severe inflammation by releasing anti-inflammatory factors that counteract and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending to at least 2041 in all major markets. The company’s proprietary manufacturing processes deliver cryopreserved, commercially available cellular drugs on an industrial scale. These cell therapies with defined pharmaceutical release criteria should be easily accessible to patients worldwide.

Mesoblast is developing product candidates for multiple indications based on its Remestemcel-L and Rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft-versus-host disease, bioresistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic back pain. Two…